Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study
Authors: Olivier Aubert, Nassim Kamar, Dewi Vernerey, Denis Viglietti, Frank Martinez, Jean-Paul Duong-Van-Huyen, Dominique Eladari, Jean-Philippe Empana, Marion Rabant, Jerome Verine, Lionel Rostaing, Nicolas Congy, Céline Guilbeau-Frugier, Georges Mourad, Valérie Garrigue, Emmanuel Morelon, Magali Giral, Michèle Kessler, Marc Ladrière, Michel Delahousse, Denis Glotz, Christophe Legendre, Xavier Jouven, Carmen Lefaucheur, Alexandre Loupy
Journal: BMJ (2015)

<b>Objectives</b> To assess the long term outcomes of transplantation using expanded criteria donors (ECD; donors aged ≥60 years or aged 50-59 years with vascular comorbidities) and assess the main determinants of its prognosis. <b>Design</b> Prospective, population based cohort study. <b>Setting</b> Four French referral centres. <b>Participants</b> Consecutive patients who underwent kidney transplantation between January 2004 and January 2011, and were followed up to May 2014. A validation cohort included patients from another four referral centres in France who underwent kidney transplantation between January 2002 and December 2011. <b>Main outcome measures</b> Long term kidney allograft survival, based on systematic assessment of donor, recipient, and transplant clinical characteristics; preimplantation biopsy; and circulating levels of donor specific anti-HLA (human leucocyte antigen) antibody (DSA) at baseline. <b>Results</b> The study included 6891 patients (2763 in the principal cohort, 4128 in the validation cohort). Of 2763 transplantations performed, 916 (33.2%) used ECD kidneys. Overall, patients receiving ECD transplants had lower allograft survival after seven years than patients receiving transplants from standard criteria donors (SCD; 80% <i>v</i> 88%, P&lt;0.001). Patients receiving ECD transplants who presented with circulating DSA at the time of transplantation had worse allograft survival after seven years than patients receiving ECD kidneys without circulating DSA at transplantation (44% <i>v</i> 85%, P&lt;0.001). After adjusting for donor, recipient, and transplant characteristics, as well as preimplantation biopsy findings and baseline immunological parameters, the main independent determinants of long term allograft loss were identified as allocation of ECDs (hazard ratio 1.84 (95% confidence interval 1.5 to 2.3); P&lt;0.001), presence of circulating DSA on the day of transplantation (3.00 (2.3 to 3.9); P&lt;0.001), and longer cold ischaemia time (&gt;12 h; 1.53 (1.1 to 2.1); P=0.011). Recipients of ECD kidneys with circulating DSA showed a 5.6-fold increased risk of graft loss compared with all other transplant therapies (P&lt;0.001). ECD allograft survival at seven years significantly improved with screening and transplantation in the absence of circulating DSA (P&lt;0.001) and with shorter (&lt;12 h) cold ischaemia time (P=0.030), respectively. This strategy achieved ECD graft survival comparable to that of patients receiving an SCD transplant overall, translating to a 544.6 allograft life years saved during the nine years of study inclusion time. <b>Conclusions</b> Circulating DSA and cold ischaemia time are the main independent determinants of outcome from ECD transplantation. Allocation policies to avoid DSA and reduction of cold ischaemia time to increase efficacy could promote wider implement of ECD transplantation in the context of organ shortage and improve its prognosis.